Bisphosphonates and risk of atrial fibrillation: A meta-analysis

Arthritis Research and Therapy

Volumn 12, Issue 1, 2010, Pages

  Kim, Seo Young ^a   Kim, Min Jung ^a   Cadarette, Suzanne M ^b   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; EMBASE; HEART ATRIUM FIBRILLATION; HUMAN; MEDLINE; META ANALYSIS; OSTEOPOROSIS; RISK ASSESSMENT; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; RISK FACTOR; UNITED STATES;

ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS; UNITED STATES;

EID: 77649306207     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2938     Document Type: Article

References (39)

1. National Osteoporosis Foundation: America's Bone Health: The state of osteoporosis and low bone mass in our nation. , http://www.nof.org/advocacy/prevalence/
2. Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475. 10.1359/jbmr.061113, 17144789.
3. National Osteoporosis Foundation: The clinician's guide to prevention and treatment of osteoporosis 2008. , http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf
4. Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009, 21:363-368. 10.1097/BOR.0b013e32832ca433, 19412101.
5. Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J, Cosman F, Lakatos P, Leung P, Zulema Man MD, Carlos Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue T, Sellmeyer D, Eriksen E, Cummings S. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822. 10.1056/NEJMoa067312, 17476007.
6. Cummings S, Schwartz A, Black D. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895-1896. 10.1056/NEJMc076132, 17476024.
7. Heckbert S, Li G, Cummings S, Smith N, Psaty B. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831. 10.1001/archinte.168.8.826, 18443257.
8. Chatap G, Giraud K, Vincent J. Atrial fibrillation in the elderly: facts and management. Drugs Aging 2002, 19:819-846. 10.2165/00002512-200219110-00002, 12428993.
9. Feinberg W, Blackshear J, Laupacis A, Kronmal R, Hart R. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995, 155:469-473. 10.1001/archinte.155.5.469, 7864703.
10. Hooft C, Heeringa J, Brusselle G, Hofman A, Witteman J, Kingma J, Sturkenboom M, Stricker B. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006, 166:1016-1020. 10.1001/archinte.166.9.1016, 16682576.
11. Nattel S, Opie L. Controversies in atrial fibrillation. Lancet 2006, 367:262-272. 10.1016/S0140-6736(06)68037-9, 16427496.
12. FDA Early communication of an ongoing safety review on bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel W/Calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa). FDA., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm
13. FDA Update of safety review follow-up to the October 1, 2007 'Early Communication about the Ongoing Safety Review of Bisphosphonates'. FDA., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm
14. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009, 265:581-592. 10.1111/j.1365-2796.2008.02065.x, 19141097.
15. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lappe DL, Osborn JS, Day JD. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009, 103:824-828. 10.1016/j.amjcard.2008.11.037, 19268739.
16. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE 2009, 4:e4720. 10.1371/journal.pone.0004720, 2648983, 19266096.
17. Huang W, Tsai Y, Wen Y, Hsiao F, Kuo K, Tsai C. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 2010, 17:57-63. 10.1097/gme.0b013e3181b34749, 19680161.
18. Levesque L, Blagojevic A, Etminan M, Brophy J. Oral bisphosphonates and the risk of atrial fibrillation in a cohort of older adults. Pharmacoepidemiol Drug Saf 2009, 18:S114.
19. Sorensen H, Christensen S, Mehnert F, Pedersen L, Chapurlat R, Cummings SR, Baron JA. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008, 336:813-816. 10.1136/bmj.39507.551644.BE, 2292333, 18334527.
20. Loke Y, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf 2009, 32:219-228. 10.2165/00002018-200932030-00004, 19338379.
21. Mak A, Cheung M, Ho R, Cheak A, Lau C. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 2009, 10:113. 10.1186/1471-2474-10-113, 2758833, 19772579.
22. Lesko S, Mitchell A. The use of randomized controlled trials for pharmacoepidemiology studies. Textbook of Pharmacoepidemiology 2007, 311-320. West Sussex: John Wiley & Sons, Ltd, Strom B, Kimmel S.
23. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. , http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
24. Walter S. Choice of effect measure for epidemiological data. J Clin Epidemiol 2000, 53:931-939. 10.1016/S0895-4356(00)00210-9, 11004419.
25. Zhang J, Yu K. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998, 280:1690-1691. 10.1001/jama.280.19.1690, 9832001.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
27. Egger M, Smith G, Altman D. Systematic reviews in health care. 2001, London: BMJ Publishing Group, Second.
28. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
29. Sterne J, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol 2001, 54:1046-1055. 10.1016/S0895-4356(01)00377-8, 11576817.
30. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson G, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SBMDM, . for the Meta-analysis Of Observational Studies in Epidemiology G Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA 2000, 283:2008-2012. 10.1001/jama.283.15.2008, 10789670, for the Meta-analysis Of Observational Studies in Epidemiology G.
31. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108:3006-3010. 10.1161/01.CIR.0000103131.70301.4F, 14623805.
32. Boos C, Anderson R, Lip G. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 2006, 27:136-149. 10.1093/eurheartj/ehi645, 16278230.
33. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003, 23:649-654. 10.1089/107999003322558782, 14651779.
34. Vasikaran S. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001, 38:608-623. 10.1258/0004563011901037, 11732644.
35. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007, 357:712-713.
36. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809. 10.1056/NEJMoa074941, 17878149.
37. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
38. Coory M. Comment on: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 2009,
39. Higgins J. Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 2008, 1158-1160. 10.1093/ije/dyn204, 18832388.